Natasha E. Daughtrey

Natasha Daughtrey is a partner in the firm’s Intellectual Property Litigation practice and is a member of the firm’s Life Sciences Disputes group. She joined Goodwin in 2011.

Natasha is a steadfast counselor and advocate for her clients in all aspects of intellectual property, whether she is representing them in a hotly contested litigation or by proactively guiding clients on strategies to avoid litigation altogether. Her legal practice is primarily focused on intellectual property litigation and strategic counseling, with a specialization in patents, trade secrets, and trademarks. She guides companies through all phases of IP litigation, from initial investigations to bench or jury trial and appeals. Moreover, she offers invaluable counsel to clients at various stages of their life cycle, assisting with intellectual property strategy and due diligence.

Natasha has a diverse portfolio of litigation experience, having appeared or worked on cases in federal courts, the International Trade Commission (“ITC”), and proceedings before the United States Patent and Trademark Office, including inter partes reviews. Her expertise spans a wide array of technologies, ranging from pharmaceuticals and medical devices to transmission lines, software, and cosmetics. She has been at the forefront of legal developments in intellectual property law from working on some of the earliest litigations under the Biologics Price Competition and Innovation Act (BPCIA) to advising clients on IP issues in developing cutting edge gene and cell therapies.

Natasha is also deeply committed to pro bono work, where she has advocated for clients in clemency, housing, elder law, and immigration matters. She also serves as an co-editor in Chief of Goodwin’s Big Molecule Watch blog, a vital resource in the realm of biologics, biosimilars, and the Biologics Price Competition and Innovation Act (BPCIA). Additionally, she is a key contributor to Goodwin’s Founders Workbench, an online hub for start-ups and emerging companies.

Natasha also currently serves as the co-chair of the Los Angeles chapter of Women@Goodwin where she works to hire, retain, and promote women lawyers, and has previously served on the Women in IP Committee for the Los Angeles Intellectual Property Law Association, and as an Ambassador to the Move the Needle Fund, an initiative designed to create a more diverse and inclusive legal profession.

Representative matters include:

• Representing a software developer in patent infringement proceedings before various district courts and the International Trade Commission.
• Representing innovator drug companies in Hatch Waxman litigation related to proposed generic versions of ProAir® HFA (albuterol sulfate) and Feraheme® (ferumoxytol).
• Trial counsel for Teva in a patent infringement litigation against Eli Lilly and Company related to Eli Lilly’s Emgality® (galcanezumab) product for the treatment of migraine where the jury found in favor of Teva and awarded damages of over $170 million. The case is currently on appeal at the Federal Circuit.
• Trial counsel for generic drug company in patent litigation related to its proposed generic product for treatment of idiopathic pulmonary fibrosis. After a bench trial, the court ruled in favor of the client, allowing it to launch the first generic version of the drug in the U.S.
• Representing biosimilar developers in patent infringement litigation brought by Genentech and others under the Biologics Price Competition and Innovation Act (BPCIA) related to the biosimilar rituximab product, Truxima®. The case settled favorably, allowing the biosimilar developers to launch the first rituximab biosimilar available in the U.S.
• Representing Spatz in patent infringement action brought by L’Oréal USA, Inc. related to cosmetics.
• Representing an individual in a patent infringement and unfair competition case related to electrical transmission lines.
• Representing Actavis in a patent infringement action filed by Valeant Pharmaceuticals Int’l and others under the Hatch-Waxman Act relating to Actavis’s filing of an abbreviated new drug application for generic versions of Valeant’s drug UCERIS®. At trial, the Court granted Actavis’s motion for judgment of non-infringement under Rule 52(c), allowing for the launch of a generic version of Uceris®. The Federal Circuit later upheld the trial court’s ruling.
• Representing Roxane in a patent infringement litigation filed by Prometheus in response to Roxane’s filing of an abbreviated new drug application seeking approval to market a generic version of Prometheus’s IBS treatment drug, Lotronex® (alosetron hydrochloride). After a bench trial, the District Court found in favor of Roxane that Prometheus’s patent was invalid.

Prior to joining Goodwin, Natasha was a Make a Difference Fellow at Brooklyn Legal Services Corporation A in the Individual Housing Unit where she represented tenants and tenant associations in housing litigation and appeals.

During law school, Natasha was a judicial intern to the Honorable Ronald M. Whyte, U.S. District Court for the Northern District of California and as a legal intern with the U.S. Attorney’s Office for the Southern District of California in the Civil Division. She was a member of San Diego Law Review.

Natasha has served on the Board of Directors of the Los Angeles Intellectual Property Law Association (LAIPLA), as well as the chairperson of several LAIPLA committees, and on the planning committee for the USC IP Law Institute.

The Legal 500 US named Natasha a Recommended Lawyer for her work in Patent Litigation: Full Coverage in 2024. Patexia named Natasha as a top ANDA litigator in 2020.

Natasha’s recent publications and speaking events include:

• Co-Author, “Cell Therapy Cos. Must Beware Limits Of Patent Safe Harbors,” Law360, May 2024
• Speaker, “Medicare Drug Price Negotiation: The Inflation Reduction Act and the New Paradigm in Blockbuster Drug Markets,” ACS Spring 2024: Many Flavors of Chemistry, March 2024
• Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S. 2023-2024 ed.,” published by Thomson Reuters, January 2024
• Speaker, “Litigation Financing Demystified: Insights from Funders and Counsel,” Goodwin Webinar, December 2023
• Speaker, “Generating New Clients - Part 1 Building Relationships, Networking & Prospecting,” CenterForce's Business Development Summit: Diverse Partners & Associates, November 2023
• Speaker, “Patent Dance Disclosures and Beyond: Recent Biosimilars Litigation at the District Court,” Goodwin Webinar, October 2023
• Speaker, “Celebrities & the Law — The Legal Issues of the Rich & Famous,” Goodwin Event, September 2023
• Speaker, “Think You Don’t Need to Worry About Patents Before Commercializing Your Gene or Cell Therapy Product? Think Again! The Safe Harbor and Lessons Learned from REGENXBIO v. Sarepta.,” Goodwin Webinar, August 2023
• Speaker, “Humira Biosimilar Case Study - Part I: A Matter of Exclusivity and Offset Losses,” ACI’s 14th Annual Summit on Biosimilars & Innovator Biologics, June 2023
• Speaker, “Reactions to Amgen v. Sanofi and the Future of Patent Law’s Enablement Requirement,” Goodwin Webinar, March 2023
• Speaker, “Practicing IP Law and Balancing Life,” ChIPs San Diego, February 2023
• Speaker, “A Post-Pandemic Future: Creating an Inclusive Hybrid Workplace,” Goodwin CLE Day 2022, January 2022
• Speaker, Access! AAM Annual Meeting 2021, May 2021
• Speaker, “The Hollywood Lawyer: How Popular TV Perpetuates the Idea That Lawyers Are Unethical,” Goodwin CLE Day 2021, January 2021
• Speaker, “Patent Dance Disclosures: Discovery During the Patent Dance and Beyond,” Goodwin Webinar, December 2020
• Speaker, “Women in IP: Projecting Credibility & Confidence Over Zoom,” LAIPLA, December 2020
• Moderator, Women in IP Spring Event: Genius of Women – Fireside Chat with Author Janice Kaplan, June 2020 
• Co-Author, “Five patent issues that European biosimilar developers should consider before entering the US market,” European Pharmaceutical Review, Volume 25, Issue 03, June 2020
• Speaker, “5G and SEPs on Appeal: Insights from the FTC-Qualcomm Oral Argument,” Goodwin Webinar, February 2020
• Co-Author, “US Launch: Five litigation strategies European biosimilar developers should know,” PharmaIQ, November 2019
• Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S., 2019-2020 ed.,” published by Thomson Reuters, November 2019
• Co-Author, “Medicare Negotiation and Competitive Licensing Act: An Ambitious Challenge to Biologic Patents,” Biosimilar Development, May 2019
• Co-Author, “Intellectual Property Considerations and Protectable Content in Mobile Apps,” Westlaw, June 2018 
• Co-Author, “Does Indication-Specific Pricing Fit Generics With Carveouts?,” Law360, December 2017
• “The Patent Trial and Appeal Board Second Anniversary: Reflections and Strategies for the Years Ahead,” Intellectual Property & Technology Law Journal, December 2014
• “House Passes Patent Reform Legislation,” IP Advisor, January 2014
• Co-Author, “Challenges in Asserting the Advice of Counsel Defense,” New York Law Journal, July 2012